Paper Details

  1. Home
  2. Paper Details

YKP1447, A Novel Potential Atypical Antipsychotic Agent.

Author: ChoJeong Woo, DongSeon Min, HeoJoon, JiMi Kyung, KimYong Gil, KwakByong Sung

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

YKP1447 is a novel 'atypical' antipsychotic drug that selectively binds to serotonin (5-HT(2A), Ki=0.61 nM, 5-HT(2C), Ki=20.7 nM) and dopamine (D(2), Ki=45.9 nM, D(3), Ki=42.1 nM) receptors. In behavioral studies using mice, YKP1447 antagonized the apomorphine-induced cage climbing (ED(50)=0.93 mg/kg) and DOI-induced head twitch (ED(50)=0.18 mg/kg) behavior.
Paper Details　
Original Abstract of the Article :
(S)-Carbamic acid 2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-1-phenyl-ethyl ester hydrochloride (YKP1447) is a novel "atypical" antipsychotic drug which selectively binds to serotonin (5-HT(2A), Ki=0.61 nM, 5-HT(2C), Ki=20.7 nM) and dopamine (D(2), Ki=45.9 nM, D(3), Ki=42.1 nM) receptors with over 10~1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766698/

データ提供：米国国立医学図書館（NLM）

YKP1447: A Novel Atypical Antipsychotic

The search for new and improved antipsychotic medications continues, with the aim of developing drugs with greater efficacy and fewer side effects. This study introduces YKP1447, a novel atypical antipsychotic agent, and investigates its pharmacological properties and potential therapeutic benefits. The researchers employed a combination of in vitro binding studies and behavioral experiments in mice and rats to assess the drug's activity and selectivity.

YKP1447: A Promising Atypical Antipsychotic Profile

The study found that YKP1447 demonstrated a unique atypical profile, selectively binding to serotonin (5-HT2A, 5-HT2C) and dopamine (D2, D3) receptors with high affinity. In behavioral studies, YKP1447 effectively antagonized the apomorphine-induced cage climbing and DOI-induced head twitch behaviors, suggesting antipsychotic activity. Furthermore, YKP1447 inhibited hyperactivity induced by amphetamine and the conditioned avoidance response, but only caused catalepsy at much higher doses, indicating a favorable therapeutic index.

Potential for Improved Antipsychotic Treatment

This research presents YKP1447 as a promising novel antipsychotic agent with an atypical profile and potential for fewer side effects compared to currently available drugs. Further research is needed to evaluate its clinical efficacy and safety in human subjects, but the preclinical findings suggest that YKP1447 could offer a valuable new option for the treatment of psychotic disorders.

Dr.Camel's Conclusion

This study, like a rare desert flower with medicinal properties, reveals the potential of YKP1447 as a promising new antipsychotic agent. Its atypical profile and favorable therapeutic index suggest that YKP1447, like a refreshing oasis in the desert of mental health challenges, could offer a valuable new tool for treating psychotic disorders with fewer side effects.

Date :
  1. Date Completed 2011-07-14
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19885000

DOI: Digital Object Identifier

PMC2766698

Related Literature

Article Analysis
・Side Effects of dextroamphetamine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.